{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:00:33Z","timestamp":1771455633562,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Single-pill combination therapy containing four quarter-dose medications for high blood pressure improves BP control compared to monotherapy, however patient-reported acceptance of the quadpill as a treatment strategy remains undescribed. We collected within-trial feedback and interviewed participants from the quadruple ultra-low-dose treatment for hypertension (QUARTET) trial to characterise patient attitudes to this intervention. All trial participants were asked about ease and preference for the quadpill and provided an opportunity to give further comments on the trial at 12 weeks (trial primary endpoint) and 52 weeks extended follow-up. Separately, we used purposive and quota sampling for the semi-structured telephone interviews, with the resultant verbatim transcripts analysed using an inductive thematic analysis approach. Themes were re-evaluated after each successive interview, and at suspected data saturation, an additional interview conducted for confirmation. At 12 weeks follow-up, 502 of 591 (85%) participants responded to acceptability questions, and 359 of 417 (86%) responded at week 52. Most reported the trial capsule easy or very easy to take. From eight sites, 16 participants were interviewed between 5 August 2020 and 19 November 2020. All described a positive experience, preferred once-daily morning dosing and found routine facilitated adherence. Participants valued individual responsibility for adherence, and involvement of the general practitioner in blood-pressure management. Most reported capsule size did not deter adherence but desired a smaller capsule. Participants described a preference for minimising number and dosage of medications, reduced capsule size, and once-daily morning dosing. These findings suggest a preference for single-pill combination therapy for blood pressure lowering.<\/jats:p>","DOI":"10.1038\/s41371-024-00915-4","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T09:02:17Z","timestamp":1715677337000},"page":"516-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Participants\u2019 views of ultra-low dose combination therapy for high blood pressure: a mixed-methods study from the QUARTET trial"],"prefix":"10.1038","volume":"38","author":[{"given":"Joshua G.","family":"Kovoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara K.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-7936","authenticated-orcid":false,"given":"Abdul","family":"Salam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Shiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquita S.","family":"Affandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7641-4435","authenticated-orcid":false,"given":"Michael","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma A.","family":"Figtree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Usherwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-0195","authenticated-orcid":false,"given":"Markus P.","family":"Schlaich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2522-3510","authenticated-orcid":false,"given":"Emily R.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"915_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","volume":"389","author":"NCD Risk Factor Collaboration.","year":"2017","unstructured":"NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37\u201355.","journal-title":"Lancet"},{"key":"915_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2016.19043","volume":"317","author":"MH Forouzanfar","year":"2017","unstructured":"Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317:165\u201382.","journal-title":"JAMA"},{"key":"915_CR3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"915_CR4","doi-asserted-by":"crossref","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u20133104.","DOI":"10.1093\/eurheartj\/ehy439"},{"key":"915_CR5","doi-asserted-by":"crossref","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71:1269\u20131324.","DOI":"10.1161\/HYP.0000000000000066"},{"key":"915_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/eurheartj\/eht407","volume":"35","author":"Working Group on the Summit on Combination Therapy for CVD.","year":"2014","unstructured":"Working Group on the Summit on Combination Therapy for CVD. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur Heart J. 2014;35:353\u201364.","journal-title":"Eur Heart J"},{"key":"915_CR7","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41569-019-0209-y","volume":"16","author":"CK Chow","year":"2019","unstructured":"Chow CK, Meng Q. Polypills for primary prevention of cardiovascular disease. Nat Rev Cardiol. 2019;16:602\u201311.","journal-title":"Nat Rev Cardiol"},{"key":"915_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.117.09202","volume":"70","author":"A Bennett","year":"2017","unstructured":"Bennett A, Chow CK, Chou M, Dehbi HM, Webster R, Salam A, et al. Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension. 2017;70:85\u201393.","journal-title":"Hypertension"},{"key":"915_CR9","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1097\/HJH.0000000000002089","volume":"37","author":"A Salam","year":"2019","unstructured":"Salam A, Atkins ER, Hsu B, Webster R, Patel A, Rodgers A. Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37:1567\u201373.","journal-title":"J Hypertens"},{"key":"915_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S0140-6736(17)30260-X","volume":"389","author":"CK Chow","year":"2017","unstructured":"Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet. 2017;389:1035\u201342.","journal-title":"Lancet"},{"key":"915_CR11","doi-asserted-by":"crossref","unstructured":"Chow CK, Atkins ER, Billot L, Chalmers J, Hillis GS, Hay P, et al. Ultra-low-dose quadruple combination blood pressure lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. Am Heart J. 2021;231:56\u201367.","DOI":"10.1016\/j.ahj.2020.09.017"},{"key":"915_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","volume":"398","author":"CK Chow","year":"2021","unstructured":"Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398:1043\u201352.","journal-title":"Lancet"},{"key":"915_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1161\/CIRCOUTCOMES.115.001483","volume":"8","author":"H Liu","year":"2015","unstructured":"Liu H, Massi L, Laba TL, Peiris D, Usherwood T, Patel A, et al. Patients\u2019 and providers\u2019 perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial. Circ Cardiovasc Qual Outcomes. 2015;8:301\u20138.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"915_CR14","doi-asserted-by":"publisher","first-page":"e008018","DOI":"10.1136\/bmjopen-2015-008018","volume":"5","author":"F Wood","year":"2015","unstructured":"Wood F, Salam A, Singh K, Day S, Jan S, Prabhakaran D, et al. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease. BMJ Open. 2015;5:e008018.","journal-title":"BMJ Open"},{"key":"915_CR15","doi-asserted-by":"publisher","first-page":"e010458","DOI":"10.1136\/bmjopen-2015-010458","volume":"6","author":"J Jamison","year":"2016","unstructured":"Jamison J, Graffy J, Mullis R, Mant J, Sutton S. Stroke survivors\u2019, caregivers\u2019 and GPs\u2019 attitudes towards a polypill for the secondary prevention of stroke: a qualitative interview study. BMJ Open. 2016;6:e010458.","journal-title":"BMJ Open"},{"key":"915_CR16","doi-asserted-by":"publisher","first-page":"e022317","DOI":"10.1136\/bmjopen-2018-022317","volume":"8","author":"A Salam","year":"2018","unstructured":"Salam A, Webster R, Patel A, Godamunne P, Pathmeswaran A, de Silva HA, et al. Process evaluation of a randomised controlled trial of a pharmacological strategy to improve hypertension control: protocol for a qualitative study. BMJ Open. 2018;8:e022317.","journal-title":"BMJ Open"},{"key":"915_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/jme.2003.004374","volume":"30","author":"P Allmark","year":"2004","unstructured":"Allmark P. Should research samples reflect the diversity of the population? J Med Ethics. 2004;30:185\u20139.","journal-title":"J Med Ethics"},{"key":"915_CR18","first-page":"1408","volume":"20","author":"PI Fusch","year":"2015","unstructured":"Fusch PI, Ness LR. Are we there yet? Data saturation in qualitative research. Qual Rep. 2015;20:1408\u201316.","journal-title":"Qual Rep"},{"key":"915_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"915_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/104973201129119299","volume":"11","author":"R Whittemore","year":"2001","unstructured":"Whittemore R, Chase SK, Mandle CL. Validity in qualitative research. Qual Health Res. 2001;11:522\u201337.","journal-title":"Qual Health Res"},{"key":"915_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2031-8","volume":"17","author":"M Sekhon","year":"2017","unstructured":"Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17:88.","journal-title":"BMC Health Serv Res"},{"key":"915_CR22","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for Reporting Qualitative Research: A Synthesis of Recommendations. Acad Med. 2014;89:1245\u201351.","journal-title":"Acad Med"},{"key":"915_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/HYPERTENSIONAHA.122.20810","volume":"80","author":"RE Schmieder","year":"2023","unstructured":"Schmieder RE, Wassmann S, Predel H-G, Weisser B, Blettenberg J, Gillessen A, et al. Improved Persistence to Medication, Decreased Cardiovascular Events and Reduced All-Cause Mortality in Hypertensive Patients With Use of Single-Pill Combinations: Results From the START-Study. Hypertension. 2023;80:1127\u201335.","journal-title":"Hypertension"},{"key":"915_CR24","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1097\/HJH.0000000000003497","volume":"41","author":"F Rea","year":"2023","unstructured":"Rea F, Morabito G, Savar\u00e9 L, Pathak A, Corrao G, Mancia G. Adherence and related cardiovascular outcomes to single pill vs. separate pill administration of antihypertensive triple-combination therapy. J Hypertens. 2023;41:1466\u201373.","journal-title":"J Hypertens"},{"key":"915_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ijcard.2014.11.176","volume":"181","author":"M Lafeber","year":"2015","unstructured":"Lafeber M, Grobbee DE, Schrover IM, Thom S, Webster R, Rodgers A, et al. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Int J Cardiol. 2015;181:193\u20139.","journal-title":"Int J Cardiol"},{"key":"915_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.curtheres.2015.08.002","volume":"77","author":"J Fields","year":"2015","unstructured":"Fields J, Go JT, Schulze KS. Pill Properties that Cause Dysphagia and Treatment Failure. Curr Ther Res Clin Exp. 2015;77:79\u201382.","journal-title":"Curr Ther Res Clin Exp"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-024-00915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-024-00915-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-024-00915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T11:16:09Z","timestamp":1718104569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-024-00915-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1038\/s41371-024-00915-4","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"George Health Enterprises, the social enterprise arm of The George Institute for Global Health, has applied for patents in this research area, on which CKC and AR are named as inventors; George Health Enterprises has also received investment to develop fixed-dose combinations containing aspirin, statins, and BP-lowering drugs. MRN served on a Novartis Advisory Board unrelated to the work published here. GF is supported by a National Health and Medical Research Council Practitioner Fellowship (grant number APP11359290), Heart Research Australia, and the New South Wales Office of Health and Medical Research. MPS has received consulting fees, and\/or travel and research support from Medtronic, Abbott, Novartis, Servier, Pfizer, and Boehringer-Ingelheim.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was obtained from the Western Sydney Local Health Network Human Research Ethics Committee (HREC\/15\/WMEAD\/422).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}